Search
Search Results
-
Head-to-head comparison of relative cerebral blood flow derived from dynamic [18F]florbetapir and [18F]flortaucipir PET in subjects with subjective cognitive decline
BackgroundDynamic PET imaging studies provide accurate estimates of specific binding, but also measure the relative tracer delivery (R 1 ), which is a...
-
Unsupervised [18F]Flortaucipir cutoffs for tau positivity and staging in Alzheimer’s disease
PurposeSeveral [ 18 F]Flortaucipir cutoffs have been proposed for tau PET positivity (T + ) in Alzheimer’s disease (AD), but none were data-driven. The...
-
Associations between near end-of-life flortaucipir PET and postmortem CTE-related tau neuropathology in six former American football players
PurposeFlourine-18-flortaucipir tau positron emission tomography (PET) was developed for the detection for Alzheimer’s disease. Human imaging studies...
-
Monoamine oxidase binding not expected to significantly affect [18F]flortaucipir PET interpretation
Purpose[ 18 F]-labeled positron emission tomography (PET) radioligands permit in vivo assessment of Alzheimer’s disease biomarkers, including...
-
A comparison of visual assessment and semi-quantification for the diagnostic and prognostic use of [18F]flortaucipir PET in a memory clinic cohort
Purpose[ 18 F]Flortaucipir PET is a powerful diagnostic and prognostic tool for Alzheimer’s disease (AD). Tau status definition is mainly based in the...
-
Head-to-head comparison of [18F]-Flortaucipir, [18F]-MK-6240 and [18F]-PI-2620 postmortem binding across the spectrum of neurodegenerative diseases
We and others have shown that [ 18 F]-Flortaucipir, the most validated tau PET tracer thus far, binds with strong affinity to tau aggregates in...
-
International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer’s disease
PurposePositron emission tomography (PET) with the first and only tau targeting radiotracer of 18 F-flortaucipir approved by FDA has been...
-
Cross-Sectional and Longitudinal Comparison of Tau Imaging with 18F-MK6240 and 18F-Flortaucipir in Populations Matched for Age, MMSE and Brain Beta-Amyloid Burden
ObjectivesLongitudinal tau quantification may provide a useful marker of drug efficacy in clinical trials. Different tau PET tracers may have...
-
Image-level trajectory inference of tau pathology using variational autoencoder for Flortaucipir PET
PurposeAlzheimer’s disease (AD) studies revealed that abnormal deposition of tau spreads in a specific spatial pattern, namely Braak stage. However,...
-
Reduced [18F]flortaucipir retention in white matter hyperintensities compared to normal-appearing white matter
PurposeRecent research has suggested the use of white matter (WM) reference regions for longitudinal tau-PET imaging. However, tau tracers display...
-
Spatially constrained kinetic modeling with dual reference tissues improves 18F-flortaucipir PET in studies of Alzheimer disease
PurposeRecent studies have shown that standard compartmental models using plasma input or the cerebellum reference tissue input are generally not...
-
Effect of Shortening the Scan Duration on Quantitative Accuracy of [18F]Flortaucipir Studies
PurposeDynamic positron emission tomography (PET) protocols allow for accurate quantification of [ 18 F]flortaucipir-specific binding. However,...
-
A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis
PurposeThis study aims to determine whether comparable target regions of interest (ROIs) and cut-offs can be used across [ 18 F]flortaucipir, [ 18 F]RO94...
-
Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework
PurposeIn 2017, the Geneva Alzheimer’s disease (AD) Biomarker Roadmap initiative adapted the framework of the systematic validation of oncological...
-
Associations of tau, Aβ, and brain volume of the Papez circuit with cognition in Alzheimer’s disease
This study aimed to investigate the cross-sectional associations between regional Alzheimer’s disease (AD) biomarkers, including tau, β-amyloid (Aβ),...
-
Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [18F]Flortaucipir and [18F]Florbetapir Brain PET Studies
PurposeThe simplified reference tissue model (SRTM) is commonly applied for the quantification of brain positron emission tomography (PET) studies,...
-
Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study
BackgroundThe objective of this study was to make a quantitative comparison of flortaucipir PET retention with pathological tau and β-amyloid across...
-
Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
PurposeIn vivo Alzheimer’s disease (AD) biomarkers for tau pathology are cerebrospinal fluid (CSF) phosphorylated tau (p-tau) and [ 18 F]flortaucipir...
-
Tau pathology as determinant of changes in atrophy and cerebral blood flow: a multi-modal longitudinal imaging study
PurposeTau pathology is associated with concurrent atrophy and decreased cerebral blood flow (CBF) in Alzheimer’s disease (AD), but less is known...
-
Neuroimaging-guided diagnosis of possible FTLD-FUS pathology: a case report
BackgroundThis case report presents a patient with progressive memory loss and choreiform movements.
Case presentationNeuropsychological tests...
